Myeloid malignancies trang 1 tải miễn phí từ tailieunhanh

"Myeloid malignancies" trang 1 - tải miễn phí từ tailieunhanh

The importance of evaluating specific myeloid malignancies in epidemiological studies of environmental carcinogens

The importance of evaluating specific myeloid malignancies in epidemiological studies of environmental carcinogens

22 25 1

Hematologic malignancies during pregnancy: A review

Hematologic malignancies during pregnancy: A review

8 83 0

Inference of kinase-signaling networks in human myeloid cell line models by Phosphoproteomics using kinase activity enrichment analysis (KAEA)

Inference of kinase-signaling networks in human myeloid cell line models by Phosphoproteomics using kinase activity enrichment analysis (KAEA)

15 33 1

A novel miR-375-HOXB3-CDCA3/DNMT3B regulatory circuitry contributes to leukemogenesis in acute myeloid leukemia

A novel miR-375-HOXB3-CDCA3/DNMT3B regulatory circuitry contributes to leukemogenesis in acute myeloid leukemia

17 49 1

The impact of comorbid disease history on all-cause and cancer-specific mortality in myeloid leukemia and myeloma – a Swedish population-based study

The impact of comorbid disease history on all-cause and cancer-specific mortality in myeloid leukemia and myeloma – a Swedish population-based study

12 33 1

Targeting CD33 for acute myeloid leukemia therapy

Targeting CD33 for acute myeloid leukemia therapy

7 39 3

Distribution and features of hematological malignancies in Eastern Morocco: A retrospective multicenter study over 5 years

Distribution and features of hematological malignancies in Eastern Morocco: A retrospective multicenter study over 5 years

10 58 1

Targeting integrated stress response with ISRIB combined with imatinib treatment attenuates RAS/RAF/MAPK and STAT5 signaling and eradicates chronic myeloid leukemia cells

Targeting integrated stress response with ISRIB combined with imatinib treatment attenuates RAS/RAF/MAPK and STAT5 signaling and eradicates chronic myeloid leukemia cells

17 1 1

The ABNL-MARRO 001 study: A phase 1–2 study of randomly allocated active myeloid target compound combinations in MDS/MPN overlap syndromes

The ABNL-MARRO 001 study: A phase 1–2 study of randomly allocated active myeloid target compound combinations in MDS/MPN overlap syndromes

15 1 1